ライフサイエンスコーパス: deep vein

1 anges (P > .4) were small in superficial and deep veins across the spectrum of CEAP clinical classes

2 uplex ultrasonography was used to assess the deep veins before and after travel.

3 r transient thrombocytosis, 46 patients with deep vein (DVT) or arterial (ART) thrombosis and normal

4 dications ranging from serial imaging of the deep veins for 2 weeks to detect and treat only in case

5 mechanisms by which clots are formed in the deep veins have not been determined.

6 n 23, accessory veins in 34, and excessively deep veins in 19.

7 us valve failure in both the superficial and deep veins in the lower limb.

8 Thromboses limited to infrapopliteal leg deep veins (isolated distal deep vein thrombosis [IDDVT]

9 gation of clotting from superficial veins to deep veins may be regulated by shear rate, which might e

10 s, in line with valvular incompetence in the deep veins of the calf and thigh.

11 en cases of DVT (31.1%) were isolated to the deep veins of the calf.

12 Main sites of thromboses were deep veins of the extremities (10 of 23; 43%), pulmonary

13 mpression systems are successful in emptying deep veins of the lower limb and preventing stasis in a

14 confirmed symptomatic VTE (two involving the deep veins, one peripheral vein and one pulmonary emboli

15 hy can accurately depict the femoropopliteal deep veins, permitting concurrent testing for venous thr

16 Deep vein reflux was recorded in 14 of 18 participants.

17 Pulmonary emboli (PEs) and lower extremity deep vein thrombi (DVTs) were formed in five dogs, then

18 ent of thrombi structurally similar to human deep vein thrombi.

19 The primary outcome was deep vein thromboses (DVTs) averted.

20 ancers and symptoms, vasomotor symptoms, and deep vein thromboses with tamoxifen.

21 There were no deep vein thromboses, with 1 superfificial venous thromb

22 The annual rates of deep vein thrombosis (1.46%; range, 1.15%-1.82%), pulmon

23 were possibly associated with TRF-budesonide-deep vein thrombosis (16 mg/day) and unexplained deterio

24 ermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1A); use of stress ulcer prophylax

25 ermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1B); use of stress ulcer prophylax

26 evidence of heterogeneity between effects on deep vein thrombosis (266 versus 311, OR 0.85, 95% CI 0.

27 receiving TASQ versus 10% receiving placebo; deep vein thrombosis (4% v 0%) was more common in the TA

28 r and thromboembolic events (6/11), that is, deep vein thrombosis (4), transitory ischemic attacks (2

29 ffective than no IPC prophylaxis in reducing deep vein thrombosis (7.3% versus 16.7%; absolute risk r

30 cal practice adherence for the prevention of deep vein thrombosis (99% vs 85%, respectively; OR, 15.4

31 y status of FHMI were highest for unprovoked deep vein thrombosis (adjusted hazard ratio, 1.69; 95% c

32 ase-series method to study the risk of first deep vein thrombosis (DVT) (n=7278) and first pulmonary

33 TEEs included deep vein thrombosis (DVT) alone in 49.7%, pulmonary emb

34 y embolism (PE), whereas two thirds manifest deep vein thrombosis (DVT) alone.

35 RATIONALE: Deep vein thrombosis (DVT) and its complication pulmonar

36 Deep vein thrombosis (DVT) and its complication, pulmona

37 carefully selected patients with cancer with deep vein thrombosis (DVT) and low-risk pulmonary emboli

38 determined the association of Thr312Ala with deep vein thrombosis (DVT) and pulmonary embolism (PE) a

39 Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE),

40 Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE),

41 ratively may be at higher risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE).

42 Deep vein thrombosis (DVT) and pulmonary embolism are co

43 Deep vein thrombosis (DVT) and pulmonary embolism are co

44 Monitoring for TEE and assessment of risk of deep vein thrombosis (DVT) by the Wells prediction rule

45 Accurate detection of recurrent same-site deep vein thrombosis (DVT) is a challenging clinical pro

46 Asymptomatic deep vein thrombosis (DVT) is a complication of central

47 Deep vein thrombosis (DVT) is a low flow pathology often

48 Deep vein thrombosis (DVT) is a major cause of cardiovas

49 ssessment of suspected ipsilateral recurrent deep vein thrombosis (DVT) is a major clinical challenge

50 Deep vein thrombosis (DVT) isolated to the calf veins (d

51 Deep vein thrombosis (DVT) occurs in one-quarter of a mi

52 icoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.

53 months) and objectively documented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a

54 ing this period, one patient withdrew with a deep vein thrombosis (DVT) probably caused by an undiagn

55 Both IPC and GCS are recommended for deep vein thrombosis (DVT) prophylaxis in surgical patie

56 luation on the use of compression devices as deep vein thrombosis (DVT) prophylaxis methods in orthop

57 (4) deep vein thrombosis (DVT) prophylaxis was independent o

58 Enoxaparin sodium is widely used for deep vein thrombosis (DVT) prophylaxis, yet DVT rates re

59 Deep vein thrombosis (DVT) resolution represents a speci

60 Deep vein thrombosis (DVT) with its major complication,

61 ght lower the risk of pulmonary embolism and deep vein thrombosis (DVT), although a cause-effect rela

62 In patients with suspected lower extremity deep vein thrombosis (DVT), compression ultrasound (CUS)

63 or a first unprovoked isolated distal (calf) deep vein thrombosis (DVT), has a low risk of recurrence

64 83 (13.6%) patients; PE, in 237 (11.4%); and deep vein thrombosis (DVT), in 121 (5.8%).

65 The rates of deep vein thrombosis (DVT), pulmonary embolism (PE), and

66 The incidence rates of grade 3 or higher deep vein thrombosis (DVT), rash, bradycardia, neuropath

67 normal clot properties can predict recurrent deep vein thrombosis (DVT), we studied 320 consecutive p

68 resolution in humans after acute symptomatic deep vein thrombosis (DVT).

69 t-thrombotic syndrome (PTS) in patients with deep vein thrombosis (DVT).

70 uperficial thrombosis and the development of deep vein thrombosis (DVT).

71 ated conditions: pulmonary embolism (PE) and deep vein thrombosis (DVT).

72 rtality, all-cause mortality, and subsequent deep vein thrombosis (DVT).

73 nt (ED(50) = 0.45-0.65 mg/kg) and the rabbit deep vein thrombosis (ED(50) = 0.1-0.4 mg/kg) models.

74 ceding week lowered the risk of proximal leg deep vein thrombosis (hazard ratio, 0.46; 95% CI, 0.27-0

75 also a predictor for developing proximal leg deep vein thrombosis (hazard ratio, 1.25; 95% CI, 1.06-1

76 , 2.22; 95% confidence interval, 1.77-2.79), deep vein thrombosis (incidence rate ratio, 1.92; 95% co

77 Pediatric lower extremity deep vein thrombosis (LE-DVT) can lead to postthrombotic

78 (n = 5), nausea (n = 2), chest pain (n = 2), deep vein thrombosis (n = 1), transaminitis (n = 1), and

79 y adverse events (n = 7), cataracts (n = 4), deep vein thrombosis (n = 3), cerebral infarction (n = 2

80 3] vs 10% [67/690]; p=0.92) or recurrence of deep vein thrombosis (OR 0.93 [95% CI 0.66-1.31]; 6.4% [

81 Cs were associated with an increased risk of deep vein thrombosis (OR 2.55, 1.54-4.23, p<0.0001) but

82 ath (P = 0.007), disability (P = 0.012), and deep vein thrombosis (P = 0.048).

83 laxis compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0

84 ophylaxis to IPC further reduced the risk of deep vein thrombosis (relative risk, 0.54; 95% CI, 0.32-

85 o significant difference in the incidence of deep vein thrombosis (relative risk, 1.76 [95% CI, 0.50-

86 28, 0.97]; p=0.04; I=0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.

87 CI, 0.74, 1.08]; p=0.26; I=0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.

88 , 0.58 [95% CI, 0.34, 0.97]; p=0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.

89 6 patients (32%), and the most frequent were deep vein thrombosis (six patients), constipation (four

90 haracterization of pediatric upper extremity deep vein thrombosis (UE-DVT) and of UE postthrombotic s

91 Upper-extremity deep vein thrombosis (UEDVT) occurs spontaneously or som

92 o image experimental venous thromboembolism (deep vein thrombosis [DVT]) and pulmonary embolism (PE).

93 frapopliteal leg deep veins (isolated distal deep vein thrombosis [IDDVT]) are frequently diagnosed i

94 The FN rate was 1.14% (8/701; 7 deep vein thrombosis and 1 PE) for pooled normal, very l

95 tional interpretations versus 1.5% (9/585, 5 deep vein thrombosis and 4 PE) in trinary interpretation

96 address this, we adopted a stenosis model of deep vein thrombosis and analyzed venous thrombi in pept

97 romboembolic deterrent stockings in reducing deep vein thrombosis and appeared to be as effective as

98 ontribute to pathologies, including arterial/deep vein thrombosis and atherosclerosis.

99 mbolisms occurred, including six symptomatic deep vein thrombosis and four pulmonary emboli, resultin

100 ion, and inflammatory activity of T cells in deep vein thrombosis and its consequences for venous thr

101 tect source thrombi and culprit emboli after deep vein thrombosis and pulmonary embolism (DVT-PE).

102 In many patients with deep vein thrombosis and pulmonary embolism (venous thro

103 Deep vein thrombosis and pulmonary embolism are major he

104 or the initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as f

105 or the initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as f

106 type of heparin thromboprophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-s

107 mber 31, 2004, and in which risk factors for deep vein thrombosis and pulmonary embolism were assesse

108 ct on venous thromboembolism (which includes deep vein thrombosis and pulmonary embolism), but the ev

109 omes and Measures: Rates of symptomatic VTE (deep vein thrombosis and pulmonary embolism, confirmed b

110 Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, represents

111 Cancer patients are at increased risk of deep vein thrombosis and pulmonary embolism.

112 the mortality and morbidity associated with deep vein thrombosis and pulmonary embolism.

113 ant agents are the mainstay of treatment for deep vein thrombosis and pulmonary embolism.

114 ovoked and unprovoked events, as well as for deep vein thrombosis and pulmonary embolism.

115 ent and included serious adverse events (eg, deep vein thrombosis and systemic complications) and min

116 diagnosis of proximal or inferior vena caval deep vein thrombosis and treated with CDT from 2005 to 2

117 n between FHMI and VTE applied to unprovoked deep vein thrombosis and was not explained by modifiable

118 Outcomes for graft and deep vein thrombosis are not favorable.

119 arket and are believed to reduce the risk of deep vein thrombosis by 40%.

120 eduction in risk of the specific endpoint of deep vein thrombosis compared with no statin use (RR 0.7

121 8-year-old German-Caucasian man arrived with deep vein thrombosis DVT, pain, oedema and rubor of righ

122 Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%.

123 The prevalence of deep vein thrombosis following decannulation from extrac

124 Principal outcomes were deep vein thrombosis in both the lower and upper extremi

125 on factors are known to be a risk factor for deep vein thrombosis in humans.

126 measure of relative risk, the odds ratio for deep vein thrombosis in subjects with GlcCer levels belo

127 The prevalence of deep vein thrombosis in the cannulated vessel following

128 describe the prevalence of postdecannulation deep vein thrombosis in the cannulated vessel in adults

129 ormatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis included patients aged 65 years or

130 However, the risk of subsequent deep vein thrombosis increased by 50% among VCF patients

131 ltrate the thrombus and vein wall rapidly on deep vein thrombosis induction and remain in the tissue

132 Deep vein thrombosis is a major global health issue, res

133 e of symptomatic central venous line-related deep vein thrombosis is associated with worse outcomes,

134 treatment of acute proximal lower-extremity deep vein thrombosis is increasing in the United States

135 Deep vein thrombosis occurred in 5 patients.

136 Obesity is a risk factor for deep vein thrombosis of the leg and pulmonary embolism.

137 s Seminar, we discuss pulmonary embolism and deep vein thrombosis of the legs.

138 us thromboembolism defined as a composite of deep vein thrombosis or non-fatal or fatal pulmonary emb

139 A FN study was defined as development of deep vein thrombosis or PE within 3 months after a negat

140 y, independent of the presence or absence of deep vein thrombosis or pulmonary embolism at the time o

141 If deep vein thrombosis or pulmonary embolism is diagnosed,

142 with inflammatory bowel disease who develop deep vein thrombosis or pulmonary embolism often have ac

143 Deep vein thrombosis or pulmonary embolism were determin

144 Documented VTE (including deep vein thrombosis or pulmonary embolism) and unprovok

145 dy outcome was VTE (defined as patients with deep vein thrombosis or pulmonary embolism) that occurre

146 or cerebrovascular accident), venous events (deep vein thrombosis or pulmonary embolism), and respira

147 (ie, one or more dose received, presence of deep vein thrombosis or pulmonary embolism, or assessmen

148 role of dietary intake in the development of deep vein thrombosis or pulmonary embolus (venous thromb

149 duration of follow-up, and thrombosis type (deep vein thrombosis or pulmonary embolus).

150 with emboli in these small vessels may have deep vein thrombosis or recurrent emboli.

151 onfirmed with compression ultrasound showing deep vein thrombosis or with chest CT showing pulmonary

152 arly antithrombotics (91.46% versus 97.04%), deep vein thrombosis prophylaxis (73.79% versus 89.54%),

153 95% confidence interval [CI], 0.77 to 0.91), deep vein thrombosis prophylaxis (OR, 0.88; 95% CI, 0.83

154 ic compression (IPC) is an effective form of deep vein thrombosis prophylaxis for general surgery pat

155 flow, improve compliance with antibiotic and deep vein thrombosis prophylaxis, and improve overall pe

156 management, neurology consultation, Holter, deep vein thrombosis prophylaxis, oral hypoglycemic inte

157 oley catheter removal, R = -0.089 [P = .63]; deep vein thrombosis prophylaxis, R = 0.101 [P = .59]).

158 Measure documentation, lipid management, and deep vein thrombosis prophylaxis.

159 With the baseline PICC-related deep vein thrombosis rate of 2.7% and pooled OR of 2.55,

160 oled RR, 4.30 95% CI, 1.60-11.54) and higher deep vein thrombosis rates (2.94 1.35-6.38).

161 analysis of 11 studies comparing the risk of deep vein thrombosis related to PICCs with that related

162 Deep vein thrombosis remains a major health problem nece

163 of post thrombotic syndrome in patients with deep vein thrombosis remains unknown.

164 Deep vein thrombosis screening was performed using a rig

165 PICCs are associated with a higher risk of deep vein thrombosis than are CVCs, especially in patien

166 cal trial of patients with acute iliofemoral deep vein thrombosis treated with a fixed-dose catheter

167 in the thrombotic vein, we identify a set of deep vein thrombosis upregulated cytokines and chemokine

168 omputed tomography combined with testing for deep vein thrombosis using compression ultrasonography w

169 dies, the weighted frequency of PICC-related deep vein thrombosis was highest in patients who were cr

170 Deep vein thrombosis was induced in the inferior vena ca

171 screened high-risk patients, 20 asymptomatic deep vein thrombosis were detected with venous duplex ul

172 21 years, 52% women) with acute iliofemoral deep vein thrombosis were randomized to receive ultrasou

173 (n = 32), other venous thromboses (including deep vein thrombosis) (n = 42), and clotted devices (n =

174 for pulmonary embolism, 1% (29 of 2327) for deep vein thrombosis, 7% (61 of 866) for sepsis, 16% (22

175 Finally, complications (pulmonary embolism, deep vein thrombosis, acute respiratory distress syndrom

176 thrombus and plasma of baboons subjected to deep vein thrombosis, an example of inflammation-enhance

177 re hospitalized for proximal lower-extremity deep vein thrombosis, and 3649 patients (4.1%) underwent

178 e events were one event each of hypotension, deep vein thrombosis, and hypophosphatemia.

179 failure, urinary tract infection, pneumonia, deep vein thrombosis, and myocardial infarction were ind

180 ors for venous thromboembolism, proximal leg deep vein thrombosis, and pulmonary embolism developing

181 ent, respiratory failure, pulmonary embolism/deep vein thrombosis, and sepsis) after selected operati

182 no IVC filter vs IVC filter on PE, fatal PE, deep vein thrombosis, and/or mortality in trauma patient

183 ration rises more than 100-fold during acute deep vein thrombosis, but there are no prospective data

184 mortality, ventilator-associated pneumonia, deep vein thrombosis, depression, and hostility.

185 ab group, and grade 2 thrombosis and grade 2 deep vein thrombosis, each in one patient in the chemoth

186 eral and arterial thrombotic occlusions, and deep vein thrombosis, have been developed and evaluated.

187 rtions of treated HIV-infected patients with deep vein thrombosis, hepatitis C, renal impairment, thy

188 The use of thrombolysis for occlusive deep vein thrombosis, in attempt to reduce the long-term

189 y disseminated intravascular coagulation and deep vein thrombosis, in tuberculosis (TB) patients.

190 thic VTE, including those with isolated calf deep vein thrombosis, is safe and effective.

191 For patients with acute iliofemoral deep vein thrombosis, it remains unclear whether the add

192 pulmonary embolism at 6 months, symptomatic deep vein thrombosis, major bleeding, death at 3 and 6 m

193 redictors of PE (obesity, pregnancy, cancer, deep vein thrombosis, major procedure, spinal cord paral

194 onary artery disease, obesity, hypertension, deep vein thrombosis, male sex, high-sensitivity C-react

195 mortality in the developed world, underlying deep vein thrombosis, myocardial infarction, and stroke.

196 efficacy end point was the composite of any deep vein thrombosis, nonfatal pulmonary embolism, or al

197 ts (catheter-related blood stream infection, deep vein thrombosis, occlusion, pain, infiltration, ble

198 n of statin use with venous thromboembolism, deep vein thrombosis, or pulmonary embolism in adults we

199 nd collected data on venous thromboembolism, deep vein thrombosis, or pulmonary embolism outcomes.

200 botic events (myocardial infarction, stroke, deep vein thrombosis, or pulmonary embolism) and haemorr

201 tiple arteriovenous access thromboses, prior deep vein thrombosis, prior allograft thrombosis, collag

202 ient ischemic attack, myocardial infarction, deep vein thrombosis, pulmonary embolism, and other syst

203 edical complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia)

204 s of acute renal failure requiring dialysis, deep vein thrombosis, pulmonary embolism, sepsis, pneumo

205 fibrillation, supraventricular tachycardia, deep vein thrombosis, respiratory depression, atelectasi

206 re observed in rates of postoperative ileus, deep vein thrombosis, small bowel obstruction, urinary s

207 the composite of symptomatic or asymptomatic deep vein thrombosis, symptomatic pulmonary embolism, or

208 ring the first 3 weeks symptomatic recurrent deep vein thrombosis-pulmonary embolism (DVT/PE) occurre

209 ransgenic reporter mice, we demonstrate that deep vein thrombosis-recruited TEM receive an immediate

210 , or between extrapulmonary tuberculosis and deep vein thrombosis.

211 t thrombus organization in a murine model of deep vein thrombosis.

212 ation and PAD4 as potential drug targets for deep vein thrombosis.

213 as the source of the prothrombotic effect in deep vein thrombosis.

214 ment of such diseases as atherosclerosis and deep vein thrombosis.

215 ho underwent any lower extremity imaging had deep vein thrombosis.

216 o decrease caval thrombosis in this model of deep vein thrombosis.

217 embolism manifested as pulmonary embolism or deep vein thrombosis.

218 14.5% mortality, 43.7% disability, and 9.8% deep vein thrombosis.

219 none or placebo stockings) in patients with deep vein thrombosis.

220 al stay less than 2 days, or had preexisting deep vein thrombosis.

221 ng post thrombotic syndrome in patients with deep vein thrombosis.

222 es analysed were mortality and recurrence of deep vein thrombosis.

223 rade 3 to 5 nonhematologic toxicity included deep vein thrombosis/pulmonary embolism (21%), hemorrhag

224 ively), whereas most venous studies examined deep vein thrombosis/pulmonary embolus prevention (42%)

225 clinical patients with platelet activation (deep vein thrombosis; saphenous vein graft occlusion aft

226 ially lower for pulmonary embolism (54%) and deep-vein thrombosis (44%) than heart attack (88%) and s

227 The true frequency of deep-vein thrombosis (DVT) during long-haul air travel i

228 The occurrence of deep-vein thrombosis (DVT) in patients with newly diagno

229 Deep-vein thrombosis (DVT) is regarded a chronic disease

230 FVL mutation poses a clearly higher risk for deep-vein thrombosis (DVT) than for pulmonary embolism.

231 ed with SNAC (OHEP/SNAC) in the treatment of deep-vein thrombosis (DVT).

232 mains the gold standard for the diagnosis of deep-vein thrombosis (DVT).

233 hlegmasia/VLG) after initiating treatment of deep-vein thrombosis (DVT); in 8 patients, cancer was no

234 Eligible patients with deep-vein thrombosis (EINSTEIN-DVT) or pulmonary embolis

235 al [CI], 0.51-0.90; P=0.008), including both deep-vein thrombosis (HR, 0.66; 95% CI, 0.47-0.92; P=0.0

236 rimary efficacy outcome was the composite of deep-vein thrombosis (symptomatic or asymptomatic detect

237 o cases), pulmonary embolus (two cases), and deep-vein thrombosis (three cases).

238 ge prophylaxis might reduce the frequency of deep-vein thrombosis among high-risk hospitalized patien

239 ostic techniques (compression ultrasound for deep-vein thrombosis and computed tomography pulmonary a

240 pulmonary embolism indication, patients with deep-vein thrombosis and concomitant pulmonary embolism

241 he first occurrence of pulmonary embolism or deep-vein thrombosis and performed analyses of the data

242 rophylaxis and markedly reduced the rates of deep-vein thrombosis and pulmonary embolism among hospit

243 e comprise the major arterial thromboses and deep-vein thrombosis and pulmonary embolism comprise ven

244 or the treatment and secondary prevention of deep-vein thrombosis and pulmonary embolism has been sho

245 Because the clinical diagnosis of deep-vein thrombosis and pulmonary embolism is nonspecif

246 Superficial-vein thrombosis can lead to deep-vein thrombosis and pulmonary embolism.

247 ome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembol

248 o difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary emb

249 high-dose tinzaparin developed a symptomatic deep-vein thrombosis compared with nine assigned aspirin

250 requently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulan

251 olism up to postoperative day 11, defined as deep-vein thrombosis detected by mandatory bilateral ven

252 Risk factors for deep-vein thrombosis have been shown not to be always th

253 Prophylaxis against deep-vein thrombosis in hospitalized patients remains un

254 onsecutive hospitalized patients at risk for deep-vein thrombosis in the absence of prophylaxis.

255 was symptomatic, radiographically confirmed, deep-vein thrombosis in the arm or leg or pulmonary embo

256 right-sided PICC were more likely to develop deep-vein thrombosis in the ipsilateral arm (HR 3.37, 95

257 were significantly more likely to develop a deep-vein thrombosis in the ipsilateral arm compared wit

258 Serial testing for proximal deep-vein thrombosis is a safe and effective alternative

259 Objective testing for proximal deep-vein thrombosis is useful in patients with suspecte

260 Severe peripheral neuropathy and deep-vein thrombosis occurred more frequently in the tha

261 mbolism is strongly associated with proximal deep-vein thrombosis of the legs (popliteal, femoral, or

262 0.41 to 1.45; P=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respective

263 ged at least 18 years with acute symptomatic deep-vein thrombosis or acute symptomatic pulmonary embo

264 The computer alert reduced the risk of deep-vein thrombosis or pulmonary embolism at 90 days by

265 estimates of the likelihood of freedom from deep-vein thrombosis or pulmonary embolism at 90 days we

266 clinically diagnosed, objectively confirmed deep-vein thrombosis or pulmonary embolism at 90 days.

267 oagulant drugs and SFJ ligation); subsequent deep-vein thrombosis or pulmonary embolism occurred in 9

268 ated use of medical resources; no subsequent deep-vein thrombosis or pulmonary embolism was observed

269 cial-vein thrombosis in terms of symptomatic deep-vein thrombosis or pulmonary embolism, progression

270 icacy outcome was a composite of symptomatic deep-vein thrombosis or pulmonary embolism, progression

271 ts with severe sepsis should be treated with deep-vein thrombosis prophylaxis.

272 s significantly more effective in preventing deep-vein thrombosis than 30 mg of enoxaparin twice dail

273 ly assigned 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation a

274 Deep-vein thrombosis underlies this disorder.

275 h comprised events of pulmonary embolism and deep-vein thrombosis) was more common in the PFO closure

276 ptomatic pulmonary embolism (with or without deep-vein thrombosis) were assigned to receive edoxaban

277 edications included warfarin (presumably for deep-vein thrombosis), antihypertensive agents, and a st

278 common grade three or higher toxicities were deep-vein thrombosis, 57 (26%) of 223 versus 27 (12%) of

279 physician was alerted to a patient's risk of deep-vein thrombosis, and 1251 patients to a control gro

280 A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism

281 ) with an objectively confirmed diagnosis of deep-vein thrombosis, and an indication to receive antic

282 Preoperative albumin, postoperative deep-vein thrombosis, and electrolyte levels were associ

283 ostate cancer, hypertension, hyperlipidemia, deep-vein thrombosis, and stroke.

284 outcome was the composite of any symptomatic deep-vein thrombosis, any nonfatal pulmonary embolism, a

285 ein thrombosis, or asymptomatic proximal-leg deep-vein thrombosis, as detected with the use of system

286 e, non-interventional study of patients with deep-vein thrombosis, done in hospitals and community ca

287 h-dose tinzaparin was superior in preventing deep-vein thrombosis, it was associated with a higher ra

288 mboembolism, pulmonary embolism, symptomatic deep-vein thrombosis, or asymptomatic proximal-leg deep-

289 bilateral venography, documented symptomatic deep-vein thrombosis, or documented symptomatic pulmonar

290 he composite secondary end point of proximal deep-vein thrombosis, pulmonary embolism, and death (2.7

291 Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical

292 All women who had a recorded diagnosis of deep-vein thrombosis, venous thrombosis not otherwise sp

293 mptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twi

294 d anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory mo

295 erythrodysesthesia, cerebral ischaemia, and deep-vein thrombosis.

296 and unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.

297 elated bloodstream infection and symptomatic deep-vein thrombosis.

298 of graduated compression stockings (GCS) for deep vein thrombus (DVT) prophylaxis in acute stroke pat

299 Furthermore, unresolved human deep vein thrombus specimens stained positively with ant

300 e-way movement of blood from superficial and deep veins towards the heart.